Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
6,047 total articles
Zevia (ZVIA) looks set for a tactical rebound. The stock trades near $1.42 after carving a base above its February low; balance-sheet liquidity, reasonable valuation (EV/Sales ~0.42), and concentrated short interest create a setup where earnings and margin stabilization could trigger a rapid move higher. This is a medium-risk swing trade sized for …
Marvell is benefitting from a structural move away from copper networking toward optics inside hyperscale data centers. Strong data-center revenue, a high-growth product slate (Teralynx switch, DCI optics), and renewed momentum after a public endorsement create an actionable trade setup. We outline entry, stop and target levels for a long position …
SpaceX's imminent IPO and a credible path to a 2027 Tesla-SpaceX combination materially raise the expected upside for Tesla equity. Tesla's $1.59T market cap, strong cash position and AI/semiconductor roadmap make it a plausible acquirer or merger partner. We upgrade the stance and lay out an actionable long trade with precise entry, stop and targe…
TG Therapeutics' positive Phase 1 subcutaneous BRIUMVI results represent a clear de-risking event for the company’s flagship MS franchise. With accelerating sales, raised guidance, a reasonable P/E of ~13x, and significant short interest, the stock offers an asymmetric opportunity. We outline an actionable long trade with entry, target, and stop, a…
Duke Energy is courting technology companies to manage the execution risk on its large capital projects tied to AI and data-center driven electrification. The company trades at about $121.54, yields ~3.5%, and carries a market cap near $94.8B. This trade idea recommends a long position with entry at $121.54, a target of $134.00 and a stop at $115.0…
Rocket Lab’s stock at roughly $118 is pricing an almost impossibly successful Neutron rollout into valuation. With a market cap near $68B, negative free cash flow, and an EV/sales north of 96x, the risk-reward favors sellers until Neutron demonstrates reliable, repeatable economics. This trade targets a pullback over the next 45 trading days with a…
Aurinia (AUPH) is trading near 52-week highs but still offers a reasonable valuation: market cap roughly $2.1B, trailing EPS about $2.32 and free cash flow of $166.6M. The business generates cash today while late-stage lupus/lupus nephritis market dynamics and guideline shifts create meaningful catalysts over the next 3-6 months. Trade plan: long A…
Danone is trading near the low end of its 52-week range despite tangible progress on strategic moves: confirmed 2026 guidance, the Huel acquisition, a dairy JV in Argentina, and strengthened funding for precision fermentation partners. The stock looks like a dairy multiple but the company is increasingly a platform play in functional nutrition. We …
Atour Lifestyle is building scale across hotels and retail experiences while returning cash to shareholders. With a $4.85B market cap, mid-30s valuation, and accelerating revenue growth, ATAT is a candidate for a long trade into a catalyst window (dividend, buybacks, travel recovery). The trade below balances upside to the 52-week highs with a defi…
We upgrade Mondelez to a buy for a swing trade. The company offers steady free cash flow, a 3.2% yield, and improving revenue momentum as cocoa prices ease — all while the shares sit below their 52-week high and technicals show room to run. Entry at $62.43, stop at $58.50 and targets at $67.00 and $71.15 for a mid-term (45 trading days) hold.
Alkami (ALKT) looks primed for a re-rating after a large institutional purchase, strong recent revenue growth and talk of a shareholder vote around a buyback. The balance of improving fundamentals and continued execution risk makes this a medium-risk, long-term trade: entry $16.70, stop $14.10, target $24.00 over roughly 180 trading days.
Atour Lifestyle (ATAT) has the ingredients for another leg higher: rapid room rollouts, double-digit revenue growth, a shareholder-friendly capital allocation push and an upcoming dividend distribution. Technicals are mixed today, but a disciplined entry around the $35 area with a tight stop and a target near the 52-week highs gives a favorable ris…
Grifols is trading cheaply (market cap $6.42B, P/E ~10.6, P/B ~0.81) while the underlying plasma-derived therapies market is growing strongly. Near-term headline risk out of Canada has hit the stock, but resolution or containment of that regulatory episode, combined with improved plasma self-sufficiency trends and continued demand for immunoglobuli…
NBT Bancorp (NBTB) trades at a modest P/E of ~12.7 and a P/B near 1.22, pays a 3.2% yield, and has scale ($16.11B assets) following the Evans Bancorp merger. This trade targets $52 with a $40 stop, keyed to stable fundamentals, improving footprint in Upstate New York, and attractive cash flow metrics.
Microchip Technology is showing early signs of margin stabilization while its data center business is scaling quickly. With the Data Center Solutions unit posting $302.7M in 2025 and management projecting roughly $500M in 2026 (a 65% increase), the stock can re-rate if margins and free cash flow continue improving. This is a tactical swing trade: e…
Blue Moon Metals is shifting from an exploration story to construction-ready projects after a string of asset deals, strategic share placements and a 35k-45k meter 2026 drilling program. At a $561.8M market cap and $7.79 share price, the stock has momentum but carries execution and financing risk. This trade idea offers a defined long with entry, s…
Trip.com (TCOM) is trading well under its 52-week high after a January regulatory scare. Under the surface, domestic travel demand and the group’s global distribution footprint remain intact. At a $33.9B market cap and a P/E of 7.2, the stock looks inexpensive if Trip.com can navigate the antitrust scrutiny. This is a tactical long with a clear sto…
OFG Bancorp trades at single-digit P/E and modest multiples, but elevated profitability and a concentrated Puerto Rico footprint limit the company’s ability to meaningfully expand EPS. Given technical resistance near the 52-week high and bearish momentum, a tactical short with a conservative stop and mid-term target offers asymmetric risk-reward.
Cadence Design Systems (CDNS) sits squarely in the software layer that enables modern chip design. Fundamentals show healthy cash generation and returns, while the market is pricing rapid growth into a premium multiple. We see a high-probability swing trade to the long side: enter on current weakness, use a tight stop to limit downside, and target …
JPMorgan's low-coupon fixed-rate preferreds retain appeal as a yield overlay and balance-sheet play versus other cash instruments. Using the common as a proxy, we lay out an actionable long trade: entry at $303.00, stop at $285.00, target at $335.00 over a 180-trading-day horizon, backed by strong capital metrics, predictable net interest income, a…
Visa is not cheap on headline multiples, yet the company’s cash flow profile, ROE and network economics argue for a constructive trade. Entry at $316, stop at $300, target $360 over a mid-term (45 trading day) horizon. Risk/reward is reasonable for a capital-light monopoly with secular tailwinds in digital payments.
Chipotle's share price has been hammered to a 52-week low near $28.16 despite healthy fundamentals: $1.51B in free cash flow, ROE above 60%, and a market cap around $36.9B. Technicals show an oversold reset and heavy short interest that can accelerate a bounce. This is a tactical swing idea to capture mean reversion to the low-$30s while limiting d…
Strategy Inc (MSTR) is trading at a steep discount to the market value of its Bitcoin treasury. The business is loss-making as an operating company but sits on a massive crypto balance sheet and growing yield-linked product activity. This trade idea lays out an entry at $127.00, stop at $105.00, and a $240.00 target over a long-term (180 trading da…
AgomAb Therapeutics is a small-cap clinical-stage biotech with a pair of late-stage-ish catalysts in H2 2026, a newly granted U.S. patent for its inhaled ALK5 program, and roughly $116.5M in cash on the balance sheet. The shares trade at $12.00 today with a $585M market cap; this trade idea proposes a speculative long for event-driven upside while …
Micron's rally has pushed multiples into stratospheric territory: P/E ~50, P/B ~16.8 and EV/EBITDA ~32.9 while FCF yield sits below 1%. That premium implies the market is pricing sustained, outsized growth. If the AI-driven memory boom cools or flows rotate to storage/enterprise SSD names (including Sandisk-related stocks), MU is vulnerable to a si…
